The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis

To investigate treatment outcomes, hearing outcomes, and adverse effects of rituximab (RTX) for intractable otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV).

Source: Auris, Nasus, Larynx - June 6, 2018 Category: ENT & OMF Authors: Masahiro Okada, Koichiro Suemori, Daiki Takagi, Masato Teraoka, Hiroyuki Yamada, Jun Ishizaki, Takuya Matsumoto, Hitoshi Hasegawa, Naohito Hato Source Type: research